SCHEMBL3407136

SCHEMBL3407136

CCOc1ccc(-c2ncc[nH]2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.76
CYP3A4 P08684 2/20 0.76
CYP2D6 P10635 2/20 0.76
CYP2C9 P11712 2/20 0.76
CYP2C19 P33261 2/20 0.76
CYP19A1 P11511 1/20 0.76
NISCH Q9Y2I1 2/20 0.59
KCNH2 Q12809 1/20 0.54
HRH3 Q9Y5N1 1/20 0.54
MTOR P42345 1/20 0.53
ADK P55263 1/20 0.53
ALDH1A1 P00352 6/20 0.53
KDM4E B2RXH2 5/20 0.53
RAB9A P51151 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
HSD17B10 Q99714 3/20 0.53
HPGD P15428 2/20 0.53
GAA P10253 1/20 0.53
ALOX15 P16050 1/20 0.53
MPI P34949 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL10336733 0.95 CYP1A2 (0.69) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4723343 0.86 CYP1A2 (0.88) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4723390 0.86 CYP2D6 (1.00) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL14599590 0.85 CYP1A2 (0.70) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL6002465 0.82 CYP2D6 (0.91) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL771769 0.81 CYP1A2 (0.65) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL15764580 0.81 CYP1A2 (0.65) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL6941842 0.81 CYP1A2 (0.73) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL722191 0.80 NISCH (0.78) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL12462292 0.80 CYP1A2 (0.72) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101735217-B Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug UNIV GUANGDONG PHARM 2012-09-26 CN claimed
CN-101863894-B Tanshinone II A derivative and preparation method and application thereof UNIV GUANGDONG PHARM 2012-07-18 CN claimed
CN-101863894-A Tanshinone II A derivative and preparation method and application thereof GUANGDONG PHARMACEUTICAL UNIVERSITY 2010-10-20 CN claimed
CN-101735217-A Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug UNIV GUANGDONG PHARM 2010-06-16 CN claimed
CN-1034174-C Certain imidazoquinoxalines, a new class of GABA brain receptor ligands NEUROGEN CORP (US) 1997-03-05 CN claimed
CN-1076930-A Some imidazo quinoxaline compound; The γ-An Jidingsuan brain receptor ligands that one class is new NEUROGEN CORP (US) 1993-10-06 CN claimed
CN-101735217-B Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug UNIV GUANGDONG PHARM 2012-09-26 CN disclosed
CN-101863894-B Tanshinone II A derivative and preparation method and application thereof UNIV GUANGDONG PHARM 2012-07-18 CN disclosed
EP-2254871-A1 SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AS IONIC FLUIDS Technische Universität Dresden (DE) 2010-12-01 EP disclosed
CN-101863894-A Tanshinone II A derivative and preparation method and application thereof GUANGDONG PHARMACEUTICAL UNIVERSITY 2010-10-20 CN disclosed
CN-101735217-A Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug UNIV GUANGDONG PHARM 2010-06-16 CN disclosed
WO-2009095012-A1 SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AND THE USE THEREOF Technische Universität Dresden (DE) 2009-08-06 WO disclosed
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed
CN-1034174-C Certain imidazoquinoxalines, a new class of GABA brain receptor ligands NEUROGEN CORP (US) 1997-03-05 CN disclosed
CN-1076930-A Some imidazo quinoxaline compound; The γ-An Jidingsuan brain receptor ligands that one class is new NEUROGEN CORP (US) 1993-10-06 CN disclosed
US-4956470-A BACTERICIDES, FUNGICIDES, ANTHELMINTICS, ANTIPROTOZOA AGENTS HOFFMANN-LA ROCHE INC. (US) 1990-09-11 US disclosed
US-4814332-A PARASITICIDES HOFFMAN-LA ROCHE INC. (US) 1989-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 CYP1A2 427/4885CYP3A4 152/4885CYP2D6 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.